Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.03 or -3.95% from the prior close of $0.76. The stock opened at $0.8 and touched a ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company, has issued registered ordinary shares of ...

Shares of Calvin Klein-owner PVH Corp and genetic testing company Illumina fell on Tuesday after China placed the two ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

Analyst Michael Cherny of Leerink Partners maintained a Hold rating on Walgreens Boots Alliance (WBA – Research Report), retaining the price ...